Elite Pharmaceuticals, Inc. Derivative Liability, Noncurrent
Elite Pharmaceuticals, Inc. (ELTP) had Derivative Liability, Noncurrent of $17.34 million as of 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-13
- 2026-03-31: Derivative Liability, Noncurrent $17.34M.
- 2025-12-31: Derivative Liability, Noncurrent $27.97M.
- 2025-09-30: Derivative Liability, Noncurrent $39.79M.
- 2025-06-30: Derivative Liability, Noncurrent $47.31M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-03-31 | $17.34M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $27.97M 10-Q · filed 2026-02-17 |
| 2025-09-30 | $39.79M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $47.31M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $25.20M 10-K · filed 2026-06-29 |
| 2024-12-31 | $33.57M 10-Q · filed 2026-02-17 |
| 2024-09-30 | $21.84M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $9.08M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $6.30M 10-K · filed 2026-06-29 |
| 2023-12-31 | $5.60M 10-Q · filed 2025-02-13 |
| 2023-09-30 | $3.18M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $711.08K 10-Q · filed 2024-08-14 |
| 2023-03-31 | $521.71K 10-Q · filed 2025-02-13 |
| 2022-12-31 | $375.77K 10-Q · filed 2024-02-14 |
| 2022-09-30 | $748.66K 10-Q · filed 2023-11-14 |
| 2022-06-30 | $1.44M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $936.84K 10-Q · filed 2024-02-14 |
| 2021-12-31 | $838.85K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $1.33M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.75M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $2.36M 10-K · filed 2022-06-29 |